Gregory Zante

Gregory Zante

Director of Finance/CFO at VIKING THERAPEUTICS, INC.

Net worth: 17 M $ as of 2024-03-30

53 year
Health Technology
Commercial Services
Consumer Services

Profile

Gregory S.
Zante
is currently the Chief Financial Officer at Viking Therapeutics, Inc. He previously held positions as the Director-Finance & Administration at Calyx Therapeutics, Inc., the Senior Vice President at Matrix Pharmaceutical, Inc., the Senior Staff Accountant at Ernst & Young LLP, the Vice President-Finance & Administration at Sangamo Therapeutics, Inc., and the Chief Financial Officer at Aerami Therapeutics, Inc. Mr. Zante obtained his undergraduate degree from the University of California, Los Angeles.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-03-26 207,361 ( 0.19% ) 17 M $ 2024-03-30

Gregory Zante active positions

CompaniesPositionStart
VIKING THERAPEUTICS, INC. Director of Finance/CFO 2021-01-03
All active positions of Gregory Zante

Former positions of Gregory Zante

CompaniesPositionEnd
Director of Finance/CFO 2015-12-31
SANGAMO THERAPEUTICS, INC. Chief Administrative Officer 2013-05-31
Corporate Officer/Principal 2001-11-30
Corporate Officer/Principal 1995-10-31
See the detail of Gregory Zante's experience

Training of Gregory Zante

University of California, Los Angeles Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Gregory Zante's experience

Connections

100 +

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
SANGAMO THERAPEUTICS, INC.

Health Technology

VIKING THERAPEUTICS, INC.

Health Technology

Private companies3

Health Technology

Commercial Services

Health Technology

See company connections